Research map: Therapeutic management of resectable mismatch-repair deficient/microsatellite instability-high gastroesophageal adenocarcinoma: a real-world analysis from Austria

Back to the article

Papers in this map

  1. Comprehensive molecular characterization of gastric adenocarcinoma · Adam Joel Bass · 2014 · 6688 citations · Cited by this paper
  2. Tackling similarities and differences in global practice guidelines for gastric cancer: a review on the latest Taiwan guidelines with Asia-Pacific, European and US guidelines · 2026 · Related
  3. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial · Yelena Yuriy Janjigian · 2021 · 3119 citations · Cited by this paper
  4. Artificial intelligence–based anatomical recognition improves surgeon decision-making during robotic gastrectomy · 2026 · Related
  5. Adjusting for multiple testing—when and how? · Ralf Bender · 2001 · 3030 citations · Cited by this paper
  6. Simple clinical parameters to identify sarcopenia 1 year after gastrectomy for gastric cancer · 2026 · Related
  7. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations · A.M. Mandard · 1994 · 2069 citations · Cited by this paper
  8. A proof-of-concept study of surgical-VLM for surgical support in robotic surgery: contextual benchmarking against ChatGPT-5 · 2026 · Related
  9. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial · Yung‐Jue Bang · 2012 · 1749 citations · Cited by this paper
  10. Plasma proteomic signatures improve risk stratification and personalized screening for gastric cancer · 2026 · Related
  11. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Florian Lordick · 2022 · 1526 citations · Cited by this paper
  12. Early- versus late-onset gastroesophageal cancer: real-world outcomes from a 13-year central European cohort study · 2026 · Related
  13. Mismatch Repair Deficiency, Microsatellite Instability, and Survival · Elizabeth Catherine Smyth · 2017 · 537 citations · Cited by this paper
  14. Comment on ‘Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer’ · 2026 · Related
  15. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer · Filippo Pietrantonio · 2019 · 497 citations · Cited by this paper
  16. Racial/ethnic and geographic differences in second primary cancers in stomach cancer survivors: a comparative study of U.S. and South Korea · 2026 · Related
  17. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials · Joseph Chao · 2021 · 463 citations · Cited by this paper
  18. Total versus subtotal gastrectomy following neoadjuvant flot chemotherapy for distal diffuse gastric adenocarcinoma: an international cohort study · 2026 · Related
  19. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study · Thierry André · 2022 · 410 citations · Cited by this paper
  20. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study · Kohei Shitara · 2023 · 388 citations · Cited by this paper
  21. Gastric cancer · Raghav Sundar · 2025 · 377 citations · Cited by this paper
  22. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer · Yelena Yuriy Janjigian · 2025 · 319 citations · Cited by this paper
  23. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer · Minsuk Kwon · 2021 · 252 citations · Cited by this paper
  24. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial · Sylvie Lorenzen · 2023 · 228 citations · Cited by this paper
  25. Nonoperative Management of Mismatch Repair–Deficient Tumors · Andrea Cercek · 2025 · 216 citations · Cited by this paper
  26. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials · Filippo Pietrantonio · 2021 · 200 citations · Cited by this paper
  27. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO · A. Raimondi · 2024 · 95 citations · Cited by this paper
  28. Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study · Florian Lordick · 2024 · 61 citations · Cited by this paper
  29. Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study · Kohei Shitara · 2025 · 48 citations · Cited by this paper
  30. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study · Ning Li · 2024 · 39 citations · Cited by this paper
  31. How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force · Christelle de la Fouchardière · 2025 · 27 citations · Cited by this paper
  32. LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma · J. Tabernero · 2025 · 21 citations · Cited by this paper
  33. 1448P IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts · Christelle de la Fouchardière · 2024 · 15 citations · Cited by this paper
  34. Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis · Alessandra Raimondi · 2025 · 14 citations · Cited by this paper
  35. Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol · Florian Huemer · 2022 · 13 citations · Cited by this paper
  36. Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns · Martin Korpan · 2025 · 12 citations · Cited by this paper
  37. Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study · Liying Zhao · 2025 · 9 citations · Cited by this paper
  38. Proportion and distribution of PD-L1 expression and associated clinicopathologic features in patients with microsatellite instability-high gastric cancer. · Sun Mi Lee · 2024 · 4 citations · Cited by this paper
  39. Surgery in Older Cancer Patients · Ka Yu Keith Cheung · 2026 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)